Pradipta Ghosh, MD
Rheumatology · Loma Linda
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Faculty Physicians and Surgeons of Llusm · County of Riverside
Hospitals listed: Loma Linda University Medical Center · Riverside University Health System-Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ghosh’s office at (909) 558-2154 to ask if they take your plan before you enroll.
California Medical Board record
Licence A96208 · Current
Licensed to practise in California · since 2006 · expires 2028-02-29 · Marshall University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MD.MD.60088193Physician And Surgeon License · since 2009 · expires 2012-02-24ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Loma Linda University Medical CenterLoma Linda, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Loma Linda University Health, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.71 (0.47 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.146, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.468, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.383, Oct 2024 – Sep 2025
- Riverside University Health System-Medical CenterMoreno Valley, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Riverside University Health SystemPatients rate it 2 of 5 · 66% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.232, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Loma Linda University Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.71 (0.47 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.146 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.468 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.383 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.66 (0 to 1.53) · 2,053 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 173.35 (135.58 to 211.11) · 169 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 79 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 272 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 421 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,758 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,732 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.15 to 0.52) · 8,479 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.88 (1.14 to 4.63) · 2,571 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.04 (0 to 2.41) · 933 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.66 to 4.04) · 2,380 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.16 (0.2 to 10.13) · 908 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.42 (0.42 to 6.42) · 988 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.29 (0.91 to 3.67) · 677 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 0.85) · 7,115 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 37 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.685 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.702 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.4 · 380 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 660 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 15.1 · 167 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 29.6 · 365 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.5 · 282 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.6 · 513 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (4 to 7.3) · 422 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.2 to 15.5) · 422 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 89 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 190 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 18.1) · 720 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 778 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,684 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Riverside University Health System-Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.232 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.38 (0.38 to 2.38) · 932 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.93 (0.56 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 191.06 (136.87 to 245.25) · 59 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,070 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 4,158 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.35 (0.15 to 0.55) · 4,169 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.15 to 5.76) · 582 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.29) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.8 (0.71 to 18.89) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.67 (0.57 to 8.78) · 125 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 159 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0 to 1.09) · 3,702 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 48 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.517 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.896 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.404 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 46 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 303 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.1 · 162 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1 · 164 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 290 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (3.8 to 9.1) · 36 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.9 (8.1 to 16.7) · 36 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 60 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 151 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.3 to 17) · 127 cases | No different | Jan 2022 – Dec 2024 |
What patients said (416 patients answered, 10% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$6,363
Medicare paid this office $6,363 for 57 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,186 | $104 |
| Return visit (30+ min) | 14 | $1,396 | $100 |
Who their Medicare patients are
57 Original Medicare patients in 2024. Average age 72 · Women 74% · Also on Medicaid 65% · Health risk score 2.62. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Diabetes 47% · Chronic kidney disease 42% · Heart failure 40% · COPD 32% · Atrial fibrillation 32% · Coronary heart disease 28% · Dementia 28% · Depression 26% · Cancer 25% · Stroke 23%.
The office billed $24,285, Medicare allowed $8,154 and paid $6,363; for 68 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$87,463 in 2024
Medicaid paid $87,463 for 1,080 billed services this clinician did in 2024, up to 46 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 287 | $77,409 |
| Return visit (30+ min) | 486 | $9,192 |
| Screening for depression is documented as negative, a follow-up plan is not required | 143 | $862 |
| Alcohol and/or drug screening | 164 | $0 |
| 2024 | 1,080 | 4 | 46 | $87,463 |
Drugs they prescribed that Part D paid
$323,523
Pharmacies billed $323,523 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 248) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
211 generic and fewer than 11 brand-name prescriptions · $323,523 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 15 | $139,916 | $9,328 |
| Hydroxychloroquine Sulfate | 40 | $1,078 | $27 |
| Mycophenolate Mofetil | 17 | $745 | $44 |
| Methotrexate | 31 | $712 | $23 |
| Gabapentin | 18 | $578 | $32 |
See all 8 drugs
| Humira(Cf) | 15 | $139,916 | $9,328 |
| Hydroxychloroquine Sulfate | 40 | $1,078 | $27 |
| Mycophenolate Mofetil | 17 | $745 | $44 |
| Methotrexate | 31 | $712 | $23 |
| Gabapentin | 18 | $578 | $32 |
| Leflunomide | 12 | $371 | $31 |
| Prednisone | 13 | $102 | $8 |
| Allopurinol | 12 | $54 | $5 |
Year by year
| 2024 | 248 | 84 | 0% (0) | None | $323,523 |
| 2023 | 646 | 305 | 0% (0) | None | $475,540 |
| 2022 | 1,259 | 329 | 1% (11) | None | $886,841 |
| 2021 | 1,032 | 247 | None | None | $781,197 |
| 2020 | 1,002 | 236 | None | None | $662,070 |
| 2019 | 871 | 241 | None | None | $513,693 |
| 2018 | 992 | 258 | None | None | $489,486 |
| 2017 | 929 | 255 | None | None | $367,173 |
| 2016 | 822 | 225 | None | None | $297,613 |
| 2015 | 721 | 235 | 3% (20) | None | $224,225 |
| 2014 | 649 | 216 | 4% (23) | 33% | $225,420 |
| 2013 | 521 | 199 | 2% (12) | 37% | $104,840 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Enbrel Sureclick | 17 | $89,046 | $5,238 |
| Orencia | 14 | $62,637 | $4,474 |
| Enbrel | 14 | $58,025 | $4,145 |
| Xeljanz | 13 | $44,023 | $3,386 |
| Actemra Actpen | 16 | $30,124 | $1,883 |
| Amjevita(Cf) | 13 | $23,645 | $1,819 |
| Rasuvo | 21 | $18,090 | $861 |
| Methotrexate | 147 | $2,598 | $18 |
| Hydroxychloroquine Sulfate | 78 | $2,496 | $32 |
| Mycophenolate Mofetil | 23 | $2,478 | $108 |
| Leflunomide | 38 | $1,437 | $38 |
| Prednisone | 85 | $1,200 | $14 |
| Diclofenac | 13 | $420 | $32 |
| Allopurinol | 18 | $192 | $11 |
| Alendronate | 16 | $166 | $10 |
| Meloxicam | 11 | $114 | $10 |
2022: 25 drugs
| Enbrel Sureclick | 30 | $153,946 | $5,132 |
| Enbrel | 34 | $148,905 | $4,380 |
| Orencia | 30 | $126,187 | $4,206 |
| Humira | 24 | $116,083 | $4,837 |
| Xeljanz | 31 | $71,579 | $2,309 |
| Humira | 12 | $57,782 | $4,815 |
| Actemra Actpen | 20 | $57,287 | $2,864 |
| Rasuvo | 51 | $57,209 | $1,122 |
| Humira(Cf) | 11 | $49,114 | $4,465 |
| Methotrexate | 292 | $6,051 | $21 |
| Mycophenolate Mofetil | 42 | $4,980 | $119 |
| Hydroxychloroquine Sulfate | 86 | $4,547 | $53 |
| Leflunomide | 98 | $4,325 | $44 |
| Prednisone | 207 | $2,683 | $13 |
| Sulfasalazine | 19 | $772 | $41 |
| Diclofenac | 19 | $576 | $30 |
| Allopurinol | 37 | $537 | $15 |
| Gabapentin | 24 | $476 | $20 |
| Colchicine | 13 | $409 | $31 |
| Leucovorin | 15 | $355 | $24 |
| Duloxetine | 15 | $260 | $17 |
| Meloxicam | 20 | $199 | $10 |
| Celecoxib | 12 | $194 | $16 |
| Omeprazole | 13 | $140 | $11 |
| Alendronate | 11 | $112 | $10 |
2021: 20 drugs
| Enbrel | 63 | $287,840 | $4,569 |
| Xeljanz | 29 | $79,653 | $2,747 |
| Enbrel Sureclick | 16 | $78,840 | $4,927 |
| Humira | 15 | $63,524 | $4,235 |
| Humira | 14 | $61,418 | $4,387 |
| Humira(Cf) | 12 | $50,683 | $4,224 |
| Rasuvo | 38 | $46,301 | $1,218 |
| Methotrexate | 265 | $6,256 | $24 |
| Leflunomide | 89 | $5,115 | $57 |
| Hydroxychloroquine Sulfate | 71 | $3,598 | $51 |
| Mycophenolate Mofetil | 26 | $3,545 | $136 |
| Prednisone | 150 | $3,531 | $24 |
| Sulfasalazine | 25 | $752 | $30 |
| Pilocarpine | 17 | $641 | $38 |
| Diclofenac | 22 | $528 | $24 |
| Leucovorin | 20 | $516 | $26 |
| Allopurinol | 30 | $448 | $15 |
| Gabapentin | 19 | $390 | $21 |
| Meloxicam | 16 | $161 | $10 |
| Alendronate | 14 | $146 | $10 |
2020: 15 drugs
| Enbrel | 55 | $241,658 | $4,394 |
| Xeljanz Xr | 22 | $87,527 | $3,978 |
| Xeljanz | 36 | $84,357 | $2,343 |
| Humira | 17 | $64,204 | $3,777 |
| Rasuvo | 38 | $53,909 | $1,419 |
| Orencia | 11 | $42,734 | $3,885 |
| Methotrexate | 284 | $6,792 | $24 |
| Leflunomide | 105 | $6,510 | $62 |
| Mycophenolate Mofetil | 25 | $3,927 | $157 |
| Prednisone | 168 | $3,852 | $23 |
| Hydroxychloroquine Sulfate | 64 | $3,061 | $48 |
| Sulfasalazine | 24 | $1,271 | $53 |
| Diclofenac | 28 | $1,039 | $37 |
| Leucovorin | 14 | $389 | $28 |
| Allopurinol | 12 | $225 | $19 |
2019: 15 drugs
| Enbrel | 51 | $218,459 | $4,284 |
| Xeljanz Xr | 18 | $65,858 | $3,659 |
| Orencia | 14 | $51,350 | $3,668 |
| Rasuvo | 39 | $48,412 | $1,241 |
| Xeljanz | 21 | $47,025 | $2,239 |
| Humira | 11 | $44,724 | $4,066 |
| Leflunomide | 78 | $8,410 | $108 |
| Methotrexate | 255 | $6,235 | $24 |
| Mycophenolate Mofetil | 21 | $4,319 | $206 |
| Prednisone | 166 | $3,767 | $23 |
| Hydroxychloroquine Sulfate | 39 | $3,605 | $92 |
| Diclofenac | 25 | $1,411 | $56 |
| Sulfasalazine | 17 | $987 | $58 |
| Gabapentin | 11 | $622 | $57 |
| Meloxicam | 14 | $112 | $8 |
2018: 16 drugs
| Enbrel | 50 | $216,642 | $4,333 |
| Xeljanz | 28 | $81,539 | $2,912 |
| Rasuvo | 47 | $50,815 | $1,081 |
| Xeljanz Xr | 11 | $37,153 | $3,378 |
| Leflunomide | 67 | $23,847 | $356 |
| Methotrexate | 277 | $16,642 | $60 |
| Colchicine | 12 | $5,364 | $447 |
| Prednisone | 194 | $5,050 | $26 |
| Hydroxychloroquine Sulfate | 88 | $4,186 | $48 |
| Diclofenac | 30 | $1,583 | $53 |
| Gabapentin | 24 | $1,139 | $47 |
| Sulfasalazine | 17 | $1,137 | $67 |
| Duloxetine | 24 | $761 | $32 |
| Allopurinol | 12 | $302 | $25 |
| Alendronate | 16 | $203 | $13 |
| Meloxicam | 16 | $142 | $9 |
2017: 15 drugs
| Enbrel | 41 | $161,375 | $3,936 |
| Enbrel Sureclick | 11 | $42,810 | $3,892 |
| Xeljanz | 12 | $37,635 | $3,136 |
| Rasuvo | 25 | $31,386 | $1,255 |
| Leflunomide | 70 | $25,889 | $370 |
| Methotrexate | 295 | $15,821 | $54 |
| Colchicine | 16 | $5,368 | $336 |
| Hydroxychloroquine Sulfate | 54 | $4,781 | $89 |
| Prednisone | 191 | $4,603 | $24 |
| Diclofenac | 23 | $1,295 | $56 |
| Sulfasalazine | 13 | $1,231 | $95 |
| Allopurinol | 18 | $625 | $35 |
| Gabapentin | 11 | $450 | $41 |
| Meloxicam | 28 | $281 | $10 |
| Alendronate | 17 | $242 | $14 |
2016: 10 drugs
| Enbrel | 49 | $178,487 | $3,643 |
| Leflunomide | 69 | $20,447 | $296 |
| Methotrexate | 262 | $15,134 | $58 |
| Hydroxychloroquine Sulfate | 53 | $12,539 | $237 |
| Colchicine | 27 | $9,935 | $368 |
| Prednisone | 171 | $4,785 | $28 |
| Sulfasalazine | 15 | $2,152 | $143 |
| Allopurinol | 21 | $1,001 | $48 |
| Meloxicam | 34 | $394 | $12 |
| Alendronate | 18 | $262 | $15 |
2015: 11 drugs
| Enbrel | 33 | $89,295 | $2,706 |
| Humira | 25 | $66,706 | $2,668 |
| Methotrexate | 196 | $7,830 | $40 |
| Prednisone | 185 | $5,723 | $31 |
| Colchicine | 20 | $5,556 | $278 |
| Leflunomide | 59 | $5,328 | $90 |
| Hydroxychloroquine Sulfate | 33 | $4,799 | $145 |
| Voltaren | 16 | $1,049 | $66 |
| Allopurinol | 17 | $1,040 | $61 |
| Hydrocodone-Acetaminophen | 11 | $398 | $36 |
| Alendronate | 11 | $164 | $15 |
2014: 11 drugs
| Enbrel | 45 | $101,254 | $2,250 |
| Humira | 30 | $66,794 | $2,226 |
| Methotrexate | 183 | $15,674 | $86 |
| Colcrys | 25 | $12,194 | $488 |
| Leflunomide | 53 | $5,562 | $105 |
| Prednisone | 137 | $4,180 | $31 |
| Sulfazine | 11 | $1,221 | $111 |
| Allopurinol | 30 | $1,036 | $35 |
| Hydroxychloroquine Sulfate | 23 | $928 | $40 |
| Voltaren | 15 | $906 | $60 |
| Hydrocodone-Acetaminophen | 14 | $272 | $19 |
2013: 8 drugs
| Enbrel | 25 | $52,271 | $2,091 |
| Colcrys | 34 | $16,946 | $498 |
| Methotrexate | 102 | $7,827 | $77 |
| Prednisone | 152 | $3,448 | $23 |
| Leflunomide | 33 | $3,357 | $102 |
| Hydroxychloroquine Sulfate | 22 | $928 | $42 |
| Sulfazine | 12 | $880 | $73 |
| Allopurinol | 28 | $828 | $30 |
Money from drug and device companies
$119 in 2024
A payment is not proof that care is biased.
| Aurinia Pharma U.S. | Lupkynis | $119 | 1 payment
|
See the published payment
| Aurinia Pharma U.S. | Meals · 2024-12-12 | Lupkynis | $119 |
Professional record
- NPI
- 1538219936
- Licence
- CA A96208, WA MD60088193California A96208: Current · expires 2028-02-29Washington MD.MD.60088193: Expired
- Trained
- Jc Edwards School of Medicine, Marshall University, 2004
- Group
- Faculty Physicians and Surgeons of Llusm · County of Riverside
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 710 Lawrence Expy, Department 272, Rheumatology, Santa Clara, CA, 95051
- NPI first listed
- 2007-01-10
- NPI last updated
- 2021-12-14
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.